Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:INSM)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 7, 2024

Insmed To Present at November 2024 Investor Conferences

PR Newswire November 6, 2024

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

PR Newswire October 31, 2024

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

PR Newswire October 24, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

PR Newswire October 23, 2024

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

PR Newswire October 17, 2024

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

PR Newswire October 8, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 4, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 6, 2024
View More News ››

Opinion & Analysis (NDAQ:INSM)

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Streetwise Reports February 4, 2020
View More Opinion ››

Bullboard Posts (NDAQ:INSM)

Outperform Recommendation Issued On INSM By Evercore ISI

NEWS: $INSM Outperform Recommendation Issued On INSM By Evercore ISI2024-06-21 09:15:03 ET Evercore ISI analyst issues OUTPERFORM...
whytestocks - June 21, 2024

INSM Price Target Alert: $74.00. Issued by Goldman Sachs

BREAKING NEWS: $INSM INSM Price Target Alert: $74.00. Issued by Goldman Sachs2024-05-28 16:00:07 ET Andrea Tan from Goldman Sachs issued...
whytestocks - May 28, 2024

Dow Dips Over 100 Points; GameStop Shares Spike higher | Ben

News; $INSM Dow Dips Over 100 Points; GameStop Shares Spike higher | BenzingaU.S. stocks traded mixed midway through trading, with the...
whytestocks - May 28, 2024

Insmed stock doubles on positive ASPEN study results

News; $INSM Insmed stock doubles on positive ASPEN study results2024-05-28 07:08:55 ET Shares of Insmed Inc (NASDAQ: INSM) more than...
whytestocks - May 28, 2024

RE: Upcoming FDA decision on the approval of a sma

That's nice, but you're not talking about INSM. It's is scheduled for 06/26.Please stop spamming for a not free financial rag
mornings1 - June 23, 2009

NEWS RELEASE

Momenta, Insmed May Gain From Biotech Generics Law (Update1) By Catherine Larkin March 27 (Bloomberg) -- Momenta...
sebaxter - March 27, 2008
View more Bullboard ››

FPX Nickel Corp.

FPX Nickel Corp.

FPX Nickel Corp. is a Canada-based junior nickel mining company. The Company is focused on the exploration and development of ...
View More »